SpyGlass Pharma, Inc. (SGP)
SGPNASDAQ-GSMedical/Dental Instruments
$34.18
-4.17 (-10.87%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $1.14bn
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $17.06 to $39.92
- Average volume
- 119.7k
- Previous close
- $38.35
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $39.33, +15.1% from here
Earnings
next estimate $-0.6600Next report Nov 12, 2026
Dec 2025
+13.5%
Mar 2026
-3.0%
Jun 2026
-22.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2023 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$14.23m | -$13.63m | -$15.41m | -$21.97m |
| Net income | -$13.32m | -$12.55m | -$13.82m | -$19.86m |
News
8 latest- SpyGlass Reports Four-Year Data Showing Sustained Eye Pressure Reduction With BIM-IOL System RTTNews · Oct 19, 2026
- SpyGlass Pharma Acquires Advanced Vision Science For $13 Mln In Cash RTTNews · Oct 1, 2026
- SpyGlass Pharma Q2 Loss Widens RTTNews · Aug 6, 2026
- SpyGlass Pharma, Inc. Loss At -$19.864 Mln In Q2 RTTNews · Aug 6, 2026
- HC Wainwright & Co. Initiates Coverage of SpyGlass Pharma (SGP) with Buy RecommendationFintel · Mar 10, 2026
- Stifel Initiates Coverage of SpyGlass Pharma (SGP) with Buy RecommendationFintel · Mar 3, 2026
- Citigroup Initiates Coverage of SpyGlass Pharma (SGP) with Buy RecommendationFintel · Mar 3, 2026
- Leerink Partners Initiates Coverage of SpyGlass Pharma (SGP) with Outperform RecommendationFintel · Mar 3, 2026
The company
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- spyglasspharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.